Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression
Authors:
- Sebastian MichelsSMSebastian Michels
- Chaorong ChenCCChaorong Chen
- Wolfgang P. RufWRWolfgang P. Ruf
- Frederick J. ArnoldFAFrederick J. Arnold
- Zhuoxing WuZWZhuoxing Wu
- Craig L. BennettCBCraig L. Bennett
- Daniel ShamsDSDaniel Shams
- Leslie M. ThompsonLTLeslie M. Thompson
- Alyssa C. WalkerAWAlyssa C. Walker
- Dennis W. DicksonDDDennis W. Dickson
- Leonard PetrucelliLPLeonard Petrucelli
Open Access
- 9 April 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (11)
Abstract
The role of the epigenome in age-related neurodegenerative disorders remains understudied. Here, we analyzed circulating cell-free DNA (cfDNA) from blood to detect methylation changes as a liquid biopsy for Amyotrophic Lateral Sclerosis (ALS). Our study included 20 patients with sporadic ALS, 10 patients with C9orf72-associated ALS, 10 asymptomatic carriers of the C9orf72 repeat expansion mutation, and 21 nondisease control individuals. Following targeted enzymatic methyl-sequencing (EM-seq) of approximately 4 million CpG sites, we detected numerous differentially methylated genes, including several implicated in ALS disease risk and pathogenesis. By integrating multiple epigenetic features, we delineated a distinct epigenetic signature, which achieved an average area under the curve (AUC) of 0.91 ± 0.10 upon receiver operator characteristic (ROC) analysis, which enabled detection of approximately 70% of patients with ALS with close to 100% specificity. Furthermore, we also identified a set of genes whose methylation status significantly correlated with clinical disease progression and cerebrospinal fluid (CSF) neurofilament levels. Our results reveal the potential of cfDNA-based biomarkers to accurately diagnose ALS and potentially predict disease progression.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R35 NS122140)
This publication has 65 references indexed in Scilit:
- Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral SclerosisAnnals of Neurology, 2024
- Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registryJournal of Neurology, 2023
- FUS Mutation Causes Disordered Lipid Metabolism in Skeletal Muscle Associated with ALSMolecular Neurobiology, 2022
- A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinomaHepatology Communications, 2022
- Neurofilaments in disease: what do we know?Current Opinion in Neurobiology, 2020
- Lifetime Risk and Heritability of Amyotrophic Lateral SclerosisJAMA Neurology, 2019
- Nervous NDRGs: the N-myc downstream–regulated gene family in the central and peripheral nervous systemneurogenetics, 2019
- PON1 is a disease modifier gene in amyotrophic lateral sclerosis: association of the Q192R polymorphism with bulbar onset and reduced survivalNeurological Sciences, 2019
- Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-OriginCell, 2016
- TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologiesActa Neuropathologica, 2013